Alkermes (ALKS) Stock Price, News & Analysis

Company Overview

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products. Vivitrol, a once-monthly injectable therapy for the prevention of relapse to opioid dependence following detoxification and for the treatment of alcohol dependence, represents one of the company’s cornerstone offerings. In partnership with other pharmaceutical firms, Alkermes also supports the development and commercialization of therapies such as ARISTADA (aripiprazole lauroxil) for schizophrenia and Lybalvi (olanzapine/samidorphan) for schizophrenia and bipolar I disorder. These collaborations leverage Alkermes’ formulation and delivery platforms to optimize drug release profiles and enhance patient adherence.

The company’s research and development efforts are anchored by two proprietary drug delivery platforms: ALKS 2680 microsphere technology for sustained-release injectable formulations and ATRIGEL depot technology for biodegradable, polymer-based delivery. Alkermes’ R&D pipeline includes a diverse array of small molecules and biologics targeting CNS disorders, with programs in varying stages of clinical development. These assets reflect the company’s commitment to advancing long-acting therapies that can reduce dosing frequency and improve the overall patient experience.

Established in 1987, Alkermes maintains dual headquarters in Dublin, Ireland, and Waltham, Massachusetts, and operates manufacturing facilities in Ireland and the United States. The company’s leadership is headed by Chief Executive Officer Richard F. Pops, who has overseen its growth from a research-stage enterprise into a global biopharmaceutical organization. Alkermes continues to collaborate with academic institutions, patient advocacy groups and industry partners to expand access to therapies for CNS disorders worldwide.

Key Stats

• Today's Range: $30.81 to $31.82
• 50-Day Range: $26.49 to $31.51
• 52-Week Range: $25.17 to $36.45
• Volume: 1.08 million shs
• Average Volume: 1.93 million shs
• Market Capitalization: $5.20 billion
• P/E Ratio: 15.15
• Dividend Yield: N/A
• Price Target: $42.00
• Consensus Rating: Moderate Buy

Alkermes Stock Analysis - MarketRank™

Alkermes scored higher than 90% of companies evaluated by MarketBeat, and ranked 101st out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Alkermes has a consensus price target of $42.00, representing about 33.3% upside from its current price of $31.51.

Amount of Analyst Coverage

Alkermes has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.58%

Earnings Growth

Earnings for Alkermes are expected to grow by 4.58% in the coming year, from $1.31 to $1.37 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alkermes is 15.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 234.02.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alkermes is 15.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.48.

Price to Earnings Growth Ratio

Alkermes has a PEG Ratio of 1.67. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Alkermes has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.12% of the outstanding shares of Alkermes have been sold short.

Short Interest Ratio / Days to Cover

Alkermes has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Alkermes has recently increased by 13.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alkermes does not currently pay a dividend.

Dividend Growth

Alkermes does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.17

Percentage of Shares Shorted

9.12% of the outstanding shares of Alkermes have been sold short.

Short Interest Ratio / Days to Cover

Alkermes has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Alkermes has recently increased by 13.15%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.51

News Sentiment

Alkermes has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Alkermes this week, compared to 9 articles on an average week.

Search Interest

6 people have searched for ALKS on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

MarketBeat Follows

4 people have added Alkermes to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alkermes insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.40% of the stock of Alkermes is held by insiders.

Percentage Held by Institutions

95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALKS Stock Analysis - Frequently Asked Questions

How have ALKS shares performed this year?

Alkermes' stock was trading at $28.76 on January 1st, 2025. Since then, ALKS stock has increased by 9.6% and is now trading at $31.51.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) issued its quarterly earnings results on Tuesday, July, 29th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.42 by $0.10. The business's revenue for the quarter was down 2.1% compared to the same quarter last year.
Read the conference call transcript.

Is Alkermes doing a stock buyback?

Alkermes' board approved a stock buyback plan on Thursday, February 15th 2024, which authorizes the company to buy back $400,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 8.2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.

Does Alkermes have any subsidiaries?

Alkermes subsidiaries include Rodin Therapeutics.

Who are Alkermes' major shareholders?

Top institutional investors of Alkermes include Assenagon Asset Management S.A. (0.06%) and GAMMA Investing LLC. Insiders that own company stock include Christian Todd Nichols, Craig C Hopkinson, Cato T Laurencin and Nancy Wysenski.
View institutional ownership trends.

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 10/08/2025
• Next Earnings (Estimated): 10/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALKS
• CIK: 1520262
• Web: www.alkermes.com
• Phone: (531) 772-8000
• Fax: 781-890-0524
• Employees: 1,800
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Alkermes: $42.00
• High Price Target: $52.00
• Low Price Target: $35.00
• Potential Upside/Downside: +33.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.08
• Trailing P/E Ratio: 15.15
• Forward P/E Ratio: 24.05
• P/E Growth: 1.74
• Net Income: $367.07 million
• Net Margins: 23.15%
• Pretax Margin: 27.27%
• Return on Equity: 24.86%
• Return on Assets: 17.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.23
• Quick Ratio: 2.85

Sales & Book Value

• Annual Sales: $1.56 billion
• Price / Sales: 3.34
• Cash Flow: $2.70 per share
• Price / Cash Flow: 11.69
• Book Value: $9.05 per share
• Price / Book: 3.48

Miscellaneous

• Outstanding Shares: 165,080,000
• Free Float: 157,815,000
• Market Cap: $5.20 billion
• Optionable: Optionable
• Beta: 0.54